These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 3365917)

  • 1. Rimantadine pharmacokinetics in healthy subjects and patients with end-stage renal failure.
    Capparelli EV; Stevens RC; Chow MS; Izard M; Wills RJ
    Clin Pharmacol Ther; 1988 May; 43(5):536-41. PubMed ID: 3365917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of rimantadine hydrochloride in patients with chronic liver disease.
    Wills RJ; Belshe R; Tomlinsin D; De Grazia F; Lin A; Wells S; Milazzo J; Berry C
    Clin Pharmacol Ther; 1987 Oct; 42(4):449-54. PubMed ID: 3665342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-dose pharmacokinetics of rimantadine in elderly adults.
    Tominack RL; Wills RJ; Gustavson LE; Hayden FG
    Antimicrob Agents Chemother; 1988 Dec; 32(12):1813-9. PubMed ID: 3245694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cimetidine on the disposition of rimantadine in healthy subjects.
    Holazo AA; Choma N; Brown SY; Lee LF; Wills RJ
    Antimicrob Agents Chemother; 1989 Jun; 33(6):820-3. PubMed ID: 2764530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults.
    Hayden FG; Minocha A; Spyker DA; Hoffman HE
    Antimicrob Agents Chemother; 1985 Aug; 28(2):216-21. PubMed ID: 3834831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative bioavailability of rimantadine HCl tablet and syrup formulations in healthy subjects.
    Wills RJ; Choma N; Buonpane G; Lin A; Keigher N
    J Pharm Sci; 1987 Dec; 76(12):886-8. PubMed ID: 3440931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs.
    Hoffman HE; Gaylord JC; Blasecki JW; Shalaby LM; Whitney CC
    Antimicrob Agents Chemother; 1988 Nov; 32(11):1699-704. PubMed ID: 3252751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rimantadine: a clinical perspective.
    Wintermeyer SM; Nahata MC
    Ann Pharmacother; 1995 Mar; 29(3):299-310. PubMed ID: 7606077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis.
    Foote EF; Look ZM; Giles P; Keane WF; Halstenson CE
    Am J Kidney Dis; 1995 Mar; 25(3):420-5. PubMed ID: 7872319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics.
    Hayden FG; Hoffman HE; Spyker DA
    Antimicrob Agents Chemother; 1983 Mar; 23(3):458-64. PubMed ID: 6847173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and therapeutic efficacy of rimantadine in horses experimentally infected with influenza virus A2.
    Rees WA; Harkins JD; Lu M; Holland RE; Lehner AF; Tobin T; Chambers TM
    Am J Vet Res; 1999 Jul; 60(7):888-94. PubMed ID: 10407485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rimantadine pharmacokinetics after single and multiple doses.
    Wills RJ; Farolino DA; Choma N; Keigher N
    Antimicrob Agents Chemother; 1987 May; 31(5):826-8. PubMed ID: 3606083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of a single dose of rimantadine in young adults and children.
    Anderson EL; Van Voris LP; Bartram J; Hoffman HE; Belshe RB
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1140-2. PubMed ID: 3662473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study.
    Dahlke M; Halabi A; Canadi J; Tsubouchi C; Machineni S; Pang Y
    J Clin Pharmacol; 2016 Apr; 56(4):474-83. PubMed ID: 26239266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of bepridil and two of its metabolites in patients with end-stage renal disease.
    Awni WM; Halstenson CE; Nayak RK; Opsahl JA; Desiraju RK; Minn FL; Matzke GR
    J Clin Pharmacol; 1995 Apr; 35(4):379-83. PubMed ID: 7650227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure.
    Ravis WR; Diskin CJ; Campagna KD; Clark CR; McMillian CL
    J Clin Pharmacol; 1993 Jun; 33(6):527-34. PubMed ID: 8366178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of rimantadine small-particle aerosol.
    Atmar RL; Greenberg SB; Quarles JM; Wilson SZ; Tyler B; Feldman S; Couch RB
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2228-33. PubMed ID: 2073113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.
    MacPhee IA; Spreafico S; Bewick M; Davis C; Eastwood JB; Johnston A; Lee T; Holt DW
    Kidney Int; 2000 Mar; 57(3):1164-8. PubMed ID: 10720968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.